“Efficacy of Empagliflozin as Add-on Therapy in Patients with Uncontrolled Type 2 Diabetes Mellitus”, TAJ: J of Teachers Assoc, vol. 36, no. 1, pp. 89–95, Aug. 2023, doi: 10.3329/taj.v36i1.68304.